John Harry Cross III

Insider Reports History

Location
South San Francisco, CA
Signature
/s/ Robert Cutler, attorney-in-fact
All insider transactions
Transactions in reports broken out by “transaction date” reported in original SEC filing, see here for transactions aggregated across transaction date

Holdings reported by John Harry Cross III:

Company Role Class Num Shares Value Price $ Report Date Ownership
Sonnet BioTherapeutics Holdings, Inc. Chief Financial Officer Common Stock 1,588 $1,683 $1.06 11 Dec 2023 Direct
Senti Biosciences, Inc. Chief Financial Officer Stock Option (Right to Buy) 174,200 07 Mar 2025 Direct

Insider Reports Filed by John Harry Cross III

Symbol Company Period Transactions Value $ Form Type Role Filing Time
SNTI Senti Biosciences, Inc. 07 Mar 2025 1 $0 4 Chief Financial Officer 11 Mar 2025, 16:14
SNTI Senti Biosciences, Inc. 03 Mar 2025 0 $0 3 Chief Financial Officer 11 Mar 2025, 16:14
SONN Sonnet BioTherapeutics Holdings, Inc. 11 Dec 2023 1 $0 4 Chief Financial Officer 05 Dec 2024, 21:55
SONN Sonnet BioTherapeutics Holdings, Inc. 06 Feb 2023 1 -$2,078 4 Chief Financial Officer 17 Feb 2023, 15:45
SONN Sonnet BioTherapeutics Holdings, Inc. 14 Dec 2022 1 $0 4 Chief Financial Officer 22 Dec 2022, 15:31
SONN Sonnet BioTherapeutics Holdings, Inc. 15 Dec 2021 1 $0 4 Chief Financial Officer 08 Apr 2022, 16:30